Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101
Jones, Jeffrey A., Ruppert, Amy S., Zhao, Weiqiang, Lin, Thomas S., Rai, Kanti, Peterson, Bercedis, Larson, Richard A., Marcucci, Guido, Heerema, Nyla A., Byrd, John C.Volume:
54
Language:
english
Journal:
Leukemia & Lymphoma
DOI:
10.3109/10428194.2013.788179
Date:
December, 2013
File:
PDF, 1.08 MB
english, 2013